CASI Pharmaceuticals develops and commercializes therapeutics and pharmaceutical products globally. They offer EVOMELA for multiple myeloma treatment and as conditioning treatment prior to stem cell transplantation. The company has several pipeline assets, including CNCT 19, BI-1206, CB-5339, CID-103, and Thiotepa. CASI has licensing agreements with various companies to develop and commercialize EVOMELA. They also have distribution agreements for their products globally. The company was incorporated in 1991 and is based in Beijing, China.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |